| Literature DB >> 34912746 |
Margarida Gaudêncio1, André Carvalho1, Maria Inês Bertão1, Ivo Barreiro1, Maria Isabel Bessa1, Abílio Gonçalves1.
Abstract
Cutaneous infections caused by the Mycobacterium chelonae complex show a heterogeneous clinical presentation, which varies according to the patient's immune status. Most standard antimycobacterials have no effect against these species. Clarithromycin alone was shown to provide adequate treatment, although resistance has been reported. Consequently, the literature supports multi-drug therapy to combat resistant strains. Here, we describe the case of a 59-year-old man under systemic immunosuppressive therapy who developed cutaneous lesions whose evolution was highly suggestive of atypical infection. LEARNING POINTS: Mycobacterium chelonae is a ubiquitous species of mycobacteria found in the environment; cutaneous infections by the M. chelonae complex show a heterogeneous clinical presentation.The combination of linezolid and clarithromycin has been used in some cases, with rapid clinical resolution and less or no relapse observed after long-term follow-up.Internal Medicine is the appropriate speciality to treat particularly complex or multisystem diseases, such as infections in immunocompromised patients. © EFIM 2021.Entities:
Keywords: Mycobacterium chelonae; atypical specimens; cutaneous infection; immunosuppression
Year: 2021 PMID: 34912746 PMCID: PMC8668006 DOI: 10.12890/2021_003013
Source DB: PubMed Journal: Eur J Case Rep Intern Med ISSN: 2284-2594
Figure 1Upper panel. Evolution of skin lesions. (A) The first skin lesions appeared as multiple, painful erythematous nodules distributed only over the posterior right arm. (B) After 3 months of therapy with trimethoprim/sulfamethoxazole, the skin lesions had increased and were distributed over the limbs, face, trunk and abdomen.
Lower panel. Evolution of skin lesions - continuation. (C) Erythematous papules and nodules, pustular lesions and haemorrhagic crusts distributed over limbs during hospitalization. (D) Progressive improvement in skin lesions after 9 months of therapy